The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

UBS Raises Welltower Price Target to $240, Reaffirms 'Buy' Rating

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

UBS reconfirmed its 'Buy' rating for Welltower (WELL), a leading healthcare REIT, reflecting continued confidence from analyst Michael Goldsmith. The investment bank also increased its price target for the stock from $228 to $240. This new target suggests a potential upside of 5.26% from current levels. This positive outlook contrasts with Wall Street's average price target of $219.11 for WELL. However, GuruFocus presents a more cautious view, estimating a potential downside based on its GF Value of $145.60. Despite the differing valuations, UBS's move signals a positive sentiment towards Welltower's future performance.

Sources: